Eric Sokol, MD
Urogynecology and Reconstructive Pelvic Surgery · Stanford, CANPI 1508911538
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Coloplast accounts for 70.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $631 and has fallen 56.8% since, to $273 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in CA, where the typical reported total is $4,058.
Across 25 payments — averaging $88.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$2K
- Boston Scientific$218
- Axonics, Inc.$181
- Caldera Medical, Inc$113
- Myovant Sciences Inc.$95
- Urocure LLC$37
Across 17 payments — averaging $1377.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cook Research Incorporated$11K
- Coloplast$6K
- Acell, Inc.$6K
What the payments were for
- Food & beverage$2,11595%
- Education$1005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 17 | $1,571 |
| Boston Scientific | 2 | $218 |
| Axonics, Inc. | 2 | $181 |
| Caldera Medical, Inc | 1 | $113 |
| Myovant Sciences Inc. | 2 | $95 |
| Urocure LLC | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,215 in reported general payments places this provider in the 30th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 36 | $34,352 |
| GemtesaVibegron | 22 | $18,309 |
| PremarinEstrogens, Conjugated | 23 | $9,898 |
| Estradiol | 103 | $6,280 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Stanford
- Ekene EnemchukwuStanford$15K
- Andrew BrillSan Francisco$345K
- Bilal KaakiRiverside$301K
- Savitha KrishnanMountain View$243K
- Peter CastilloLos Gatos$95K
- Bruce Kahnla Jolla$79K
- Jennifer GruenenfelderOrange$76K
- Traci ItoSan Francisco$68K
- Tanaz FerzandiLos Angeles$60K
- Sadikah BehbehaniCosta Mesa$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.